Pregenerate

What Pregenerate does

Pregenerate is a Vienna, Austria-based biotech company founded in 2019 that develops disease-on-a-chip microphysiological models aimed at accelerating drug development and enabling personalized medicine for arthritis. The company operates as a privately held for-profit entity with a headcount of 11-50 employees, consistent with an early-stage R&D-stage organization. Its underlying technology is organ-on-chip systems designed to model arthritic disease biology, which the company positions as a means to compress preclinical drug testing timelines and support patient-specific therapeutic selection.

Pregenerate's business model, as disclosed, centers on the application of its disease-on-a-chip platform to arthritis drug development; however, the input data does not specify whether revenue derives from fee-for-service collaborations with pharmaceutical partners, licensing of its platform technology, internal drug discovery, or grant-funded research. The company has been funded exclusively by SOSV (lead investor in the 2019 seed round) and RebelBio, with multiple small rounds recorded between 2019 and 2022 — the only quantified raise being $130,000 in January 2019, with subsequent events recorded at zero disclosed value. There is no evidence of commercial customers, partnerships, or revenue-generating product launches in the supplied data.

The provided product, technology, and source data also contain material inconsistencies: sections nominally attributed to Pregenerate describe an online gambling product set (Rainbet) inconsistent with a Vienna biotech profile, indicating source-data contamination. As a result, this description is constrained to firmographic, leadership, and funding information that can be cleanly attributed to Pregenerate.

Name

Pregenerate

Website

https://pregenerate.net

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Pregenerate is a Vienna-based biotech founded in 2019 that uses disease-on-a-chip microphysiological models to accelerate drug development and personalized medicine for arthritis. The early-stage company is privately backed by SOSV and RebelBio.

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Disease-on-a-chip
• Arthritis drug discovery
• Personalized medicine
• Preclinical research services
• Microphysiological systems

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. House Edge from Casino Games: Rainbet generates revenue primarily through the mathematical house edge built into its casino games including pokies, table games, live dealer games, and video poker. Players wager real money on games, and the platform retains a percentage of wagers over time.
2. Withdrawal Processing Fees: While deposits via credit cards incur a 3% fee and PayID/bank transfers are free, the platform may generate revenue through transaction processing. Withdrawal limits range from AU$50 (bank transfer) to AU$9,000 maximum.
3. VIP Program and High Roller Services: Exclusive perks, personalized bonuses, and faster cashouts offered to high rollers, potentially generating higher revenue per customer from high-value players.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Pregenerate accelerates drug development and personalized medicine for arthritis by building disease-on-a-chip biological models that recapitulate human arthritic disease states. The company supplies these microphysiological systems and associated preclinical testing services to pharmaceutical, biotechnology, and academic researchers seeking human-relevant disease models for drug screening and translational research.

Product overview

Rainbet is an Australian-focused online casino platform that launched in 2021. The platform offers a unified gaming ecosystem combining pokies/slots, table games, live dealer games, video poker, and specialty games. The core platform is accessible via desktop and mobile browsers with a responsive design. Add-on services include a VIP program for high rollers with exclusive perks. The platform integrates multiple payment providers including PayID for fast transactions and supports cryptocurrency for anonymity-conscious users.

Differentiator

Problem solved

Functional benefit

Products and services

• Arthritis Disease-on-a-Chip Platform
• Personalized Medicine Arthritis Modeling Service

Quantifiable outcome

• Withdrawals processed within 24 hours via PayID (compared to typical 3-5 days at competitors)
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• MicrogamingcoreTechnology or IntegrationMicrogaming is a pioneering online gaming software provider powering Rainbet's casino platform with games including Thunderstruck II and Mega Moolah progressive slots.
• NetEntcoreTechnology or IntegrationSwedish software innovator NetEnt provides cutting-edge graphics and popular titles like Starburst and Gonzo's Quest to Rainbet's game library.
• PlaytechcoreTechnology or IntegrationPlaytech supplies Rainbet with branded content and live dealer games including the Age of the Gods series.
• Evolution GamingcoreTechnology or IntegrationEvolution Gaming revolutionizes Rainbet's live casino with Lightning Roulette and Infinite Blackjack, streamed in high definition with professional croupiers.
• Pragmatic PlaycoreTechnology or IntegrationPragmatic Play delivers popular slots like Wolf Gold and Sweet Bonanza plus video poker variants to Rainbet's game portfolio.
• caami.orgminorGTM or Marketing Partnercaami.org is an Australian casino review and information platform that publishes detailed reviews of Rainbet, driving traffic and customer acquisition through editorial content.

Scale indicators3 records

Recent moves4 records

Expansion highlights1 record

Direct peers

• Emulate, Inc. Emulate is a leading organ-on-chip platform company offering human-relevant in vitro models (liver, intestine, lung, brain) to pharma R&D. It is the most direct competitor to Pregenerate's disease-on-a-chip approach, though Pregenerate specializes in arthritis whereas Emulate is indication-agnostic.
• CN Bio Innovations: CN Bio develops single- and multi-organ microphysiological systems (Organ-on-Chip) used for drug discovery and development. Comparable to Pregenerate in offering human-relevant in vitro disease models to pharma customers, with broader indication coverage.
• MIMETAS: MIMETAS provides organ-on-chip products (OrganoPlate) for disease modeling and drug screening. A direct peer in disease-on-chip technology, with established pharma collaborations similar to where Pregenerate is targeting.
• TissUse GmbH: TissUse develops multi-organ-chip (MOC) technology that combines multiple organ equivalents on a chip for systemic substance testing. A direct peer using microphysiological systems for disease modeling and preclinical drug testing, based in Germany like Pregenerate's regional proximity.
• InSphero AG: InSphero provides 3D in vitro disease models (organoids and microtissues) for drug discovery, with a focus on metabolic and oncology indications. Comparable to Pregenerate in offering human-relevant disease models for preclinical pharma R&D, though Pregenerate specializes in arthritis.
• Organovo Holdings: Organovo develops 3D bioprinted human tissues for drug discovery and disease modeling. A direct peer in human-relevant in vitro disease models for preclinical research, though focused on bioprinted tissue rather than microfluidic chip approaches.

Emerging players

• Hesperos, Inc. Hesperos builds multi-organ human-on-a-chip systems for systemic disease modeling and drug testing. An emerging peer with overlapping MPS-based disease modeling capabilities, though focused more on rare and neurological diseases.
• Kirkstall Ltd. Kirkstall develops Quasi Vivo, a connected cell culture system that links multiple organ models for in vitro drug testing. An emerging peer in the connected-organ-chips space, comparable to Pregenerate's disease-on-a-chip approach but with a different technical implementation.

Broad incumbents

• Recursion Pharmaceuticals: Recursion is a clinical-stage biotech using high-throughput biology and AI for drug discovery across many indications. It is a broad incumbent pursuing AI-driven drug discovery; comparable as an alternative path for pharma R&D acceleration, though it does not use organ-on-chip technology.
• Insitro: Insitro applies machine learning and high-throughput biology to drug discovery, partnering with pharma companies. It is a broad incumbent in tech-enabled drug development; relevant as an alternative model for accelerating pharma R&D but not a direct disease-on-chip competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/groups/rainbetaustralia

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pregenerate